Clinical trials: Proteinuria
C3 Glomerulopathy, Complement-mediated Kidney Disease
CHART-C3G/CLNP023B12011
This is a non-interventional chart abstraction cohort study with longitudinal follow up. Patients with C3G treated with iptacopan will be enrolled and characterized (i.e., systematically describe and summarize) regarding their…
- Conditions
- C3 Glomerulopathy, Complement-mediated Kidney Disease, Proteinuria
- Trial name
- NCT07331259
- Testing
- Iptacopan
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Nephritis
Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization Microscopy
The goal of this study is the non-invasive visualization and quantification of renal microvascular dynamics in adult kidneys with proteinuria and/or active sediment.
- Trial name
- VARIOUS (NCT07469059)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
IgA Nephropathy, Chronic Kidney Disease
Nefecon and Ambrisentan in IgA Nephropathy
Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g/24h), observing the degree and safety of reducing urinary protein and…
- Conditions
- IgA Nephropathy, Chronic Kidney Disease, Proteinuria
- Trial name
- BAIN (NCT07030894)
- Testing
- "Nefecon®","Ambrisentan"
- Where
- China
- Volunteers
- 129 people
- Sponsor
- The First Hospital of Jilin University
Type 2 Diabetes Mellitus, Albuminuria
NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
Primary objective: To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine ratio (ACR) in patients with type 2 diabetes and albuminuria Secondary objectives: To characterize the effect of study…
- Trial name
- NCT01547897
- Testing
- NOX-E36
- Where
- 24 sites in Czechia, Germany and 3 more
- Volunteers
- 76 people
- Sponsor
- TME Pharma AG